October 18, 2021

Suzi Baugh

A Win For Cancer Patients: First-of-Its-Kind Collaboration Between National Oncology Pharmacy Nonprofit and PBM

NCODA’s medically integrated pharmacy accreditation creates gold standard for oncology practices dispensing medication to patients, from first to last fill

CAZENOVIA, NYNCODA, an organization dedicated to providing oncology     patient-centered care, today announced a groundbreaking new partnership that opens the door for streamlined delivery of oncology treatments and improved patient care. The collaboration between NCODA, the leading nonprofit association for patient-centered medically integrated oncology practices, and Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM) serving more than 33 million members, represents a revolutionary shift in how cancer patients can receive their life-sustaining medications.

“This is a game changer. The result of this collaboration will without question enhance patient experience, improve health outcomes, and streamline the delivery of care for providers while reducing overall cost of care,” said Michael Reff, Founder and Executive Director of NCODA. “Empowering accredited pharmacies to work directly with patients and providers and go beyond the first fill will be transformative for patient care. We’re confident that Prime’s new IntegratedRx™ network participation requirements will revolutionize the future of oncology pharmacy.”

NCODA acted in 2014 to develop an effective model that enables oncology practices to go beyond the first fill. One of the tools used in this model is NCODA’s Cost Avoidance and Waste Tracker, a tool that has proven to enhance compliance, interventions, and the patient experience. Along with NCODA Quality Standards in place and the use of the CAWT tool, clear results were shown to payers at a local level showing that it makes more sense to keep and fill prescriptions at the individual practice. This innovative model gained attention, enabling other medically integrated oncology practices across the country to follow suit.

Today NCODA is announcing the first-ever collaboration with a PBM so the patient-centered model can be provided on a much larger scale. Through the collaboration, Prime will prefer NCODA’s recently announced Center of Excellence (CoE) Medically Integrated Pharmacy (MIP) Accreditation Program as a requisite for its IntegratedRx credentialing program.

The CoE MIP Accreditation Program is based on compliance with the American Society of Clinical Oncology/NCODA Patient-Centered Standards for Medically Integrated Dispensing. Key focus areas of the program include medication adherence, patient education and safety, cost avoidance and waste reduction, continuous quality improvement, financial assistance, and patient satisfaction.

“This program is a win-win-win for everyone,” said Jim Schwartz, RPh, NCODA President. “Allowing credentialed and accredited medically integrated oncology pharmacies to consistently fill medications for their patients will provide better patient outcomes and lower costs for the patient, practice, health plan, and employer. The MIP Accreditation Program is an unprecedented initiative that will change the way oncology patients receive their medication.”

Full details of the partnership and accreditation program will be shared at the NCODA Fall Summit in Scottsdale, AZ, from October 20-22.

For more information or to enroll in the program, visit

# # #


NCODA, the National Community Oncology Dispensing Association, is a leading nonprofit organization dedicated to empowering medically integrated oncology practices to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards, and best practices. For more information about NCODA, its Executive Council, and general updates, visit or follow @NCODAorg on Twitter.

Read More

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

– FDA approval based on phase 3 COSMIC-311 pivotal trial, which demonstrated significant improvement in progression-free survival with CABOMETYX versus placebo –

– Exelixis is prepared to fully support expanded indication immediately –

– Application approved well ahead of Prescription Drug User Fee Act target action date of December 4, 2021 –

ALAMEDA, Calif.–(BUSINESS WIRE)–Sep. 17, 2021– Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory or ineligible. The FDA granted Breakthrough Therapy designation and Priority Review to CABOMETYX and its approval comes more than two months ahead of the Prescription Drug User Fee Act (PDUFA) target action date of December 4, 2021. DTC is the most common type of thyroid cancer in the U.S., and patients who are resistant to radioactive iodine treatment face a poor prognosis.1,2,3,4

“Before today, patients with radioactive iodine-refractory differentiated thyroid cancer who have progressed following prior VEGFR-targeted therapy were facing aggressive disease and no standard treatment option,” said Marcia S. Brose, M.D., Ph.D., Chief, Cancer Center Operation Sidney Kimmel Cancer Center at Jefferson Torresdale Hospital, Co-Director, Community Based Clinical Trials, Sidney Kimmel Cancer Center at Thomas Jefferson University, and principal investigator of COSMIC-311. “In the COSMIC-311 pivotal phase 3 trial, CABOMETYX extended the time patients live without progression of their cancer. The FDA approval of CABOMETYX is an important advancement for these patients who are badly in need of new treatment options.”

Read complete release HERE


Read More

Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC

  • Approval based on Phase 1/2 trial results, which demonstrated clinically meaningful responses with a median duration of response (DoR) of approximately 1.5 years
  • Next-generation sequencing (NGS) companion diagnostic test approved simultaneously to support identification of patients with EGFR Exon20 insertion mutations

OSAKA, Japan, and CAMBRIDGE, Mass. September 15, 2021 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has approved EXKIVITY (mobocertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. EXKIVITY, which was granted priority review and received Breakthrough Therapy Designation, Fast Track Designation and Orphan Drug Designation from the FDA, is the first and only approved oral therapy specifically designed to target EGFR Exon20 insertion mutations. This indication is approved under Accelerated Approval based on overall response rate (ORR) and DoR. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.


Read More

Bristol Myers Squibb has developed a 120-mg/12-mL vial.

This vial is available in addition to the current vial sizes (40 mg, 100 mg, and 240 mg).

For NDC codes and OPDIVO storage information, see the vial flashcard HERE.

Please ensure the 120-mg vial is included in your EHR for prescribing.

If you need help adding the 120-mg vial to your EHR, contact your BMS rep or call 1-855-OPDIVO-1 (1-855-673-4861) for live support and assistance, 8:00 AM to 8:00 PM ET, Monday – Friday.

Read More



Media Contact:
Katie Edmiston | Marketing Manager


NCODA Expands Patient and Caregiver Resource to Improve Understanding and Outcomes

CAZENOVIA, NY – September 1, 2021 – With the success of the highly utilized NCODA conceived OCE (Oral Chemotherapy Education) online resource, the collaboration with the Oncology Nursing Society (ONS), the Hematology/Oncology Pharmacy Association (HOPA), and the Association of Community Cancer Centers (ACCC), has now expanded to launch the Intravenous Cancer Treatment Education (IVE) website, This website, in joint effort between the oncology healthcare providers, is dedicated to forward thinking and to providing thorough education resources to improve patient understanding.

The IVE website provides healthcare workers the latest education material for Intravenous Cancer Treatments, communicating vital information to help caregivers and their patients. With a committee consisting of representatives from each of the organizations, a development process is structured to produce trusted and reliable education sheets that provide a robust amount of information on individual drugs and combination drug regimens. The sheets include common uses and treatment schedules, supportive medications drug interactions, side effect management and safe handling tips at home following treatment.

The website is an ongoing NCODA led and committee driven project where new regimens will be added ongoing. With the launch of the IVE website, users can access the first 15 sheets and begin providing them to their patients. As additional education sheets are added, the organizations will continue to communicate this information out to their member practices.




NCODA, Inc. is a 501(c)(3) organization. Our Mission is to empower the medically-integrated oncology team to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards and best practices. For more information about NCODA’s Executive Council and general updates, visit

Read More